Jump to Main Contents
研究所ロゴ

Home > Division of Cancer RNA Research

Division of Cancer RNA Research

News

Apr. 22, 2025
A commentary written by Ryoichi Maezono has been published in the Journal of Cellular Immunology.
Apr. 21, 2025
The review article written by Masahiko Ajiro , titled -Aberrant RNA splicing regulation as a novel source of neoantigens- has been published in Japanese Journal of Cancer and Chemotherapy.
Apr. 18, 2025
Congrats to Ryoichi Maenosono―he has received the General Assembly Award at the 112th Annual Meeting of the Japanese Urological Association!!
Apr. 15, 2025
Congrats to Masahiko Ajiro ― his co–first-authored paper just came out in Science Advances!
Apr. 1, 2025
Akihide Yoshimi’s project titled 'Verification of drug discovery targeting cancer-specific cell surface receptors' has been selected for the AMED FY2025 Drug Discovery Booster.
Apr. 1, 2025
Akihide Yoshimi has been appointed as a Collaborative Professor at the Graduate School of Medicine, the University of Tokyo.
Apr. 1, 2025
Tomoya Muto's project has been accepted for a JSPS KAKENHI Grant-in-Aid for Scientific Research (B)!
Apr. 1, 2025
Asuka Kawachi's project has been accepted for a JSPS KAKENHI Grant-in-Aid for Scientific Research (C)!
Apr. 1, 2025
Parihe Muhetaer joined our team as a researcher!
Apr. 1, 2025
Kenshiro Nishihara joined our team as a researcher!
more

Our Research Interest


Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.
wordle2.png
(Figure was made by using Wordle based on our recent papers)